Mira, a California-based women’s health technology company, has introduced its Menopause Transitions Kit, a new hormone monitoring kit designed for menopausal women.
The at-home device enables women to track key hormone levels, offering real-time insights into the complex hormonal fluctuations associated with perimenopause and menopause.
The product is an AI-powered hormone monitoring device designed for women aged 35 to 60. It tracks four key reproductive hormones: follicle-stimulating hormone (FSH), luteinizing hormone (LH), pregnanediol glucuronide (PdG), which is a metabolite of progesterone, and estradiol metabolite estrone-3-glucuronide (E3G).
The Menopause Transitions Kit operates through a combination of advanced medical technology and an easy-to-use interface. The kit includes hormone-specific test wands that women can use with Mira’s AI-powered handheld analyzer.
The device reads hormone levels from urine samples, delivering precise results to the user’s smartphone through the Mira app.
Menopause is a natural phase in a woman’s life, typically occurring between the ages of 45 and 55, marked by the end of menstruation and a significant decline in hormone production, particularly estrogen and progesterone.
Menopause affects an estimated 47 million people every year, with about 47 percent of women experiencing the first symptoms of perimenopause in their mid-thirties to forties, according to Mira.
XTALKS WEBINAR: Unlock Growth in Medical Device Manufacturing with AI-Integrated eQMS
Live and On-Demand: Monday, December 9, 2024, at 11am EST (4pm GMT/UK)
Register for this free webinar to learn how AI integration can transform compliance, streamline operations and position medical device manufacturers for unprecedented growth.
The transition, known as perimenopause, can last several years and is often accompanied by symptoms like hot flashes, mood swings, sleep disturbances and changes in bone density.
Since the onset and severity of these symptoms vary widely among women, it is often a challenge to predict and manage them without personalized health insights.
In a press release, Mira CEO Sylvia Kang said, “Unfortunately, menopause remains a deeply stigmatized issue, accompanied by the lack of education for women and helpful tools to prepare. By launching the Menopause Transitions Kit, we aim to offer women a solution that informs and empowers them.”
Mira’s new hormone monitoring kit addresses the challenges of menopause by providing women with a user-friendly way to measure hormone levels that play crucial roles during the menopausal transition.
By tracking these hormones at home, women can gain a clearer understanding of how their bodies are changing, potentially improving their ability to manage symptoms and make informed decisions about their health.
The Menopause Transitions Kit aims to help users detect and manage the early stages of the menopause transition by identifying and tracking changes in reproductive stages over time. It offers metrics that can help confirm ovulation, if still occurring, with precision, says Mira.
Additionally, it helps manage menopause symptoms by correlating them with hormonal fluctuations. The monitor can also assess the impact of hormone replacement therapy (HRT) or alternative treatments in partnership with a healthcare provider or coach.
The kit also provides personalized lifestyle recommendations, highlighting key areas to monitor for better health management.
Related: From Symptoms to Solutions: Transforming Menopause Treatment with Marci English of Astellas Pharma
Mira was founded in 2015 with an initial focus on fertility monitoring. In 2018, the company launched its first hormone-tracking monitor for monitoring hormones connected to fertility.
In July, the company launched its online Hormone Health Clinic, offering personalized support from fertility specialists to individuals facing challenges with conception. The service focuses on addressing hormonal imbalances, optimizing nutrition and gut health, establishing effective exercise routines and enhancing mental well-being to improve overall fertility outcomes.
The Menopause Transitions Kit is available for pre-order on Mira’s website for $259.
Platforms like Mira’s new menopause kit are a part of a growing segment referred to as FemTech (female technology), which encompasses personalized, tech-driven solutions for women’s health needs.
Coined by entrepreneur Ida Tin in 2016, the term encompasses a broad range of products, software and services that cater to women’s health, including fertility, menstrual health, pregnancy, menopause, sexual wellness and more.
Despite making up half the world’s population, the area of women’s health has historically been neglected and even today, is often viewed as a niche market. This is posited to change as awareness around women’s unique healthcare needs grows, giving rise to demand for personalized solutions.
The FemTech market has seen exponential growth over the last decade, driven by increasing investment and the recognition of women’s specific healthcare needs.
The global FemTech market was valued at $52 billion in 2023 and could exceed $75 billion by 2025, particularly as more products target underserved areas like menopause, fertility and mental health, alongside reproductive and sexual health.
The market growth is expected to be fueled by increasing awareness of women’s health issues, advancements in healthcare technology, a growing focus on personalized medicine and the rise of digital health tools.
Notable players and products in the FemTech sector currently include the menstrual tracking apps Clue and Flo; the fertility tracking bracelet Ava and the contraceptive app Natural Cycles; as well as Gennever and Elektra Health, which offer telehealth and other forms of consultations to provide personalized care for menopausal women.
If you want your company to be featured on Xtalks.com, please email [email protected].
Join or login to leave a comment
JOIN LOGIN